Hot off the press! The 3Q10 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!

The 3Q10 OnBioVC Trend Analysis tracked, in aggregate, 70 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,420.0M. Compared to 3Q09 OnBioVC data, this investment activity represents a decrease in the number of quarter-over-quarter financings by 25 (95 v. 70) and a decrease in quarter-over-quarter invested capital of $242.9M ($1,420.0M v. $1,662.9M).

Many thanks to our wonderful partners, please show them your support!

Apredica – Preclinical ADME Tox Contract Research
BioWest – The Rocky Mountain Region’s Premiere Device & Biotech Conference
Colorado Bioscience Association – Advocacy. Representation. Service.
San Jose BioCenter – Giving emerging companies that Big Company Advantage…
Headwaters | MB – Independent middle market investment bank
Freestone Group – Integrated Solutions for Emerging Life Science
Lockton – Lifescience Industry Specific Insurance Needs
Regulus – A Full Spectrum of Regulatory Affairs and Quality Assurance Solutions
BioBeers – Where Great Minds Drink Alike…

_________________________________________________________________________

Sign up [HERE] for FREE Subscriptions to ‘Pharmaceutical Executive’ and ‘Life Science Leader’ Magazines (and other journals too!)